These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 15917704

  • 1. Combined chemoimmunotherapy of metastatic melanoma: a single institution experience.
    Di Lauro V, Scalone S, La Mura N, Zanetti M, Nigri P, Freschi A, Veronesi A.
    Melanoma Res; 2005 Jun; 15(3):209-12. PubMed ID: 15917704
    [Abstract] [Full Text] [Related]

  • 2. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO, Soori G, Wiemann MC, Schulof R, Dobbs TW, Ruben RH, DePriest CB, Church C.
    Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
    [Abstract] [Full Text] [Related]

  • 3. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
    McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB.
    Clin Cancer Res; 2000 Jun; 6(6):2201-8. PubMed ID: 10873069
    [Abstract] [Full Text] [Related]

  • 4. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A, Ascierto PA, Gravina A, Melucci MT, Palmieri G, Comella P, Cellerino R, DeLena M, Marini G, Comella G, Italian Cooperative Oncology Group.
    Cancer; 2000 Dec 15; 89(12):2630-6. PubMed ID: 11135225
    [Abstract] [Full Text] [Related]

  • 5. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
    Tarhini AA, Kirkwood JM, Gooding WE, Cai C, Agarwala SS.
    J Clin Oncol; 2007 Sep 01; 25(25):3802-7. PubMed ID: 17761969
    [Abstract] [Full Text] [Related]

  • 6. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
    Thompson JA, Gold PJ, Markowitz DR, Byrd DR, Lindgren CG, Fefer A.
    Cancer J Sci Am; 1997 Dec 01; 3 Suppl 1():S29-34. PubMed ID: 9457390
    [Abstract] [Full Text] [Related]

  • 7. Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma.
    Recchia F, Candeloro G, Necozione S, Fumagalli L, Bratta M, Rea S.
    Anticancer Drugs; 2008 Feb 01; 19(2):201-7. PubMed ID: 18176117
    [Abstract] [Full Text] [Related]

  • 8. Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
    González Cao M, Malvehy J, Martí R, Conill C, Sánchez M, Martín M, Carrera C, Herrero J, Gascón P, Mellado B, Castel T, Puig S.
    Melanoma Res; 2006 Feb 01; 16(1):59-64. PubMed ID: 16432457
    [Abstract] [Full Text] [Related]

  • 9. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
    Punt CJ, Suciu S, Gore MA, Koller J, Kruit WH, Thomas J, Patel P, Lienard D, Eggermont AM, Keilholz U.
    Eur J Cancer; 2006 Nov 01; 42(17):2991-5. PubMed ID: 17023156
    [Abstract] [Full Text] [Related]

  • 10. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
    Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC, Papadopoulos N.
    Ann Oncol; 1996 Oct 01; 7(8):827-35. PubMed ID: 8922197
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J, Lopez Hänninen E, Kirchner H, Franzke A, Körfer A, Volkenandt M, Duensing S, Schomburg A, Chaitchik S, Poliwoda H.
    Eur J Cancer; 1995 Jun 01; 31A(6):876-81. PubMed ID: 7646914
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P, Anderson C, Pearlman N, LaClaire S, Becker M, Gatlin K, O'Driscoll M, Stephens J, Gonzalez R.
    Cancer; 2002 Jan 15; 94(2):470-6. PubMed ID: 11900232
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.